# ChronoScale Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/ChronoScale Corp). ## Overview ChronoScale Corp is a U.S.-based medical robotics company focused on robotic exoskeleton systems for rehabilitation and personal mobility. Its business combines device sales, subscription-style financing arrangements, and recurring service offerings such as warranties, repairs, training, and support. ## Products & services • EksoNR rehabilitation exoskeleton • Ekso Indego Therapy clinical device • Ekso Indego Personal mobility device • EksoCare extended warranty and premium support • Device servicing, repair, and loaner devices • Customer training and clinical support - **Enterprise Health devices** (55%) — Robotic exoskeletons used in rehabilitation and clinical treatment settings. - **Personal Health devices** (20%) — Exoskeleton products sold for individual mobility and personal use. - **Subscriptions and financing-linked sales** (10%) — Device arrangements sold through financing partners or subscription terms. - **Service and support contracts** (10%) — Extended warranties, maintenance, repairs, and loaner-device services. - **Training and clinical support** (5%) — Product training and clinical onboarding delivered online or in person. - EksoNR rehabilitation exoskeleton - Ekso Indego Therapy clinical device - Ekso Indego Personal mobility device - EksoCare extended warranty and premium support - Device servicing, repair, and loaner devices - Customer training and clinical support ## Customers ChronoScale sells primarily to rehabilitation providers and healthcare organizations that use exoskeletons in clinical therapy programs, especially inpatient rehabilitation facilities and integrated delivery networks. It also serves individual users in the Personal Health market through direct or financing-supported purchase structures. In some geographies, distributors are the direct customers and act as the channel to end users. - **Enterprise Health providers** (primary) — Hospitals, rehabilitation centers, and IDNs buy EksoNR and Ekso Indego Therapy for clinical rehabilitation use. - **Personal Health users** (secondary) — Individuals and their care networks buy Ekso Indego Personal for mobility and home use. - **Distributors** (primary) — Independent distributors buy and market products in non-direct geographies, especially outside German-speaking Europe and Singapore. - **Finance partners** (secondary) — Third-party financing partners purchase devices in subscription structures and contract with end customers. - Inpatient rehabilitation facilities buying devices for therapy programs - Integrated delivery networks purchasing multi-unit clinical deployments - Long-term acute care and outpatient rehab providers using exoskeletons - Individual users buying Personal Health devices for mobility support - Finance partners and distributors acting as channel customers in some markets ## Geography ChronoScale operates across the Americas, EMEA, and APAC, with direct sales used more heavily in the Americas and German-speaking Europe and distributor-led coverage in many other markets. Revenue is exposed to regional regulatory approvals, reimbursement systems, and the pace of adoption by rehabilitation providers. The company also depends on foreign distribution partners in several countries, which affects market access and execution. - **Americas** (55%) — Estimated from narrative disclosure; direct sales are strongest here. - **EMEA** (30%) — Aggregated region; narrative indicates direct and distributor coverage. - **APAC** (15%) — Aggregated region; country mix varies by market and channel. - Americas are served mainly through a direct salesforce - EMEA uses a mix of direct sales and distributors - German-speaking Europe is handled directly - APAC relies on direct and indirect channels by country - Foreign markets require local approvals and distributor compliance ## Strategy ChronoScale is focused on expanding adoption of its rehabilitation and personal mobility devices through clinical education, reimbursement coverage, and broader product indications. It is also building recurring revenue through service contracts, training, and subscription-style sales while preparing new products such as Nomad for commercialization. The company is simultaneously evaluating strategic transactions, which adds optionality to its long-term business direction. - **Expand reimbursement and payer coverage** (short-term) — Coverage determines affordability and adoption for Personal Health and supports clinical purchasing decisions. - **Broaden indications of use** (medium-term) — More approved use cases can increase addressable demand and support product utilization in therapy settings. - **Commercialize new products** (medium-term) — New devices can refresh the portfolio and create incremental revenue streams. - **Maintain channel reach across regions** (short-term) — Distributor and direct-sales coverage are essential for market access outside core geographies. - Expand reimbursement coverage beyond CMS and other payers - Broaden product indications to support more clinical use cases - Grow Personal Health adoption through reimbursement and access - Use service, training, and warranties to deepen customer relationships - Prepare Nomad for broader commercialization - Evaluate strategic transactions alongside core execution ## Risks ChronoScale faces regulatory, reimbursement, and adoption risk because its products are used in healthcare settings and depend on approvals, payer coverage, and clinical acceptance. It also relies on distributors in several markets, which creates channel concentration and compliance risk, while competition in exoskeletons and medical robotics remains intense. As a medical device company, it is also exposed to cybersecurity, warranty, inventory, and valuation risks that can affect operations and reported results. - **Regulatory approval risk** [high] — Products must obtain and maintain approvals or clearances in each market before sale. - **Reimbursement and payer coverage risk** [high] — Personal Health demand depends on insurance coverage and reimbursement economics. - **Distributor concentration risk** [high] — Independent distributors are principal customers in several geographies and can affect access. - **Competitive technology risk** [medium] — Exoskeleton technology is early-stage and competitors can pressure features, pricing, and adoption. - **Cybersecurity risk** [medium] — The business processes sensitive data and relies on connected systems and third-party vendors. - Regulatory approvals vary by country and can delay market access - Reimbursement coverage is uncertain and affects Personal Health demand - Distributor dependence can disrupt sales in non-direct markets - Competition is intense in exoskeletons and medical robotics - Cybersecurity and data handling risks affect systems and customer data - Warranty, inventory, and valuation estimates can move reported results ## Accounting Revenue recognition is judgmental because device sales, subscriptions, warranties, and service obligations may contain multiple performance obligations and different timing patterns. Investors should also watch fair value measurements for warrants and preferred stock, inventory valuation, warranty reserves, credit loss allowances, and deferred tax asset recoverability, all of which can materially affect reported results. Lease accounting and useful-life estimates matter because the company uses specialized equipment and long-lived assets in a technology-driven product cycle. - **Revenue allocation and recognition** — Affects reported revenue timing and mix - **Fair value of warrants and preferred stock** — Can materially affect net income and equity - **Warranty and future service costs** — Affects liabilities and gross margin - **Inventory valuation** — Affects cost of sales and working capital - **Deferred tax asset recoverability** — Affects tax assets and earnings - Standalone selling prices affect allocation across device and service elements - Subscription arrangements can change timing of revenue recognition - Warranty and service reserves affect gross profit and liabilities - Inventory valuation can move margins if demand or obsolescence changes - Warrant and preferred stock fair values can create earnings volatility - Lease and useful-life estimates affect expense timing and asset values --- *Last updated: 2026-06-16T22:50:31.166243+00:00*